Does recombinant human insulin‐like growth factor‐1 have a role in the treatment of diabetes?

摘要: The structure of IGF-I is similar to that insulin, having 43 % sequence homology with human proinsulin. Both peptides can induce metabolic and mitogenic effects through their own specific receptors, which also share many structural functional similarities. Primarily involved in the regulation growth, may have a role control glucose homeostasis, facilitated by changes its binding proteins. RhIGF-I reduce hyperglycaemia patients severe insulin resistance direct mediated via receptor. Improvements sensitivity, reductions blood levels HbA1c values been seen subjects NIDDM. Enhanced sensitivity low dose rhIGF-I has observed adolescents young adults IDDM. These are closely related growth hormone levels, but there evidence complex interactions at post receptor level IGFBP-1. In recent randomised, double-blind, placebo controlled trials, given as an adjunct therapy reduced values. Although ideal dosage obtain therapeutic efficacy without complications yet be determined, important treatment diabetes. © 1997 John Wiley & Sons, Ltd.